Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

44.4%

4 terminated/withdrawn out of 9 trials

Success Rate

55.6%

-31.0% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2

6(66.7%)

Phase 3

2(22.2%)

Phase 1

1(11.1%)

9Total

Phase 2(6)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01856439Phase 1Terminated

Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease

Role: lead

NCT02708186Phase 2Completed

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

Role: lead

NCT02910102Phase 2Completed

Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia

Role: lead

NCT02586909Phase 3Terminated

12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

Role: lead

NCT02669433Phase 2Completed

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

Role: lead

NCT02871427Phase 2Terminated

Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Role: lead

NCT02585934Phase 3Completed

Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study

Role: lead

NCT02928445Phase 2Terminated

Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension

Role: lead

NCT02640729Phase 2Completed

Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia

Role: lead

All 9 trials loaded